MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1515/jpm-2025-0153

Медицинская библиотека · Journal of perinatal medicine · 2025

Evaluation of safety and performance of CentaFlow™ in the assessment of fetal growth restriction - a randomized trial and prospective cohort study.

Vedel Cathrine, Rom Ane, Wright Dave, Farlie Richard, Nielsen Lise Hald, Lauridsen Anne Hammer, Hansen Simone, Hegaard Hanne, Sander Frederikke Huitfeldt, de Wolff Mie, Petersen Olav Bjørn

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

The aim was to evaluate the sensitivity and specificity of CentaFlow (CF) in a prospective multicenter study, and secondary to evaluate the safety of the CF device in a randomized multicenter study.

METHODS

A sponsor-initiated multicenter randomized controlled clinical trial with termination of the randomization after enough women had been included to evaluate safety. The study proceeded as a prospective multicenter study including high-risk women (estimated fetal weight <-15 %, FGR). The first part randomized women to either standard care (SC) or SC+CF. Participants underwent CF evaluation with subsequent analysis for sensitivity and specificity for FGR at birth. Secondarily, adverse events were evaluated. Clinical assessments of fetal size conducted by midwives served as a reference. The performance of CF and SC was compared by McNemar's Test. The performance analysis of CF was done per-protocol sample.

RESULTS

A total of 1,601 pregnant women were enrolled, with 886 undergoing CF evaluation. A total of 123 were FGR (<3rd percentile) at birth, of which 88 were evaluated by CF, and 117 had a clinical assessment of the estimated fetal weight. CF demonstrated no evidence of benefit for detecting FGR with a sensitivity of 50 % and specificity of 43 %. Adverse events associated with CF use were limited to minor skin irritation. McNemar's test showed SC was superior to CF regarding specificity as a screening tool (p=0.014).

CONCLUSIONS

While CF was safe to use, we found no evidence that CF can be used as a predictor of FGR. Further refinement of signal analysis is necessary to enhance CFs diagnostic utility.

Для цитирования: Vedel Cathrine, Rom Ane, Wright Dave, Farlie Richard, Nielsen Lise Hald, Lauridsen Anne Hammer, Hansen Simone, Hegaard Hanne, Sander Frederikke Huitfeldt, de Wolff Mie, Petersen Olav Bjørn. Evaluation of safety and performance of CentaFlow™ in the assessment of fetal growth restriction - a randomized trial and prospective cohort study.. Journal of perinatal medicine. 2025. DOI: 10.1515/jpm-2025-0153.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.